GENOTROPIN Drug Profile

Summary for Tradename: GENOTROPIN

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for GENOTROPIN
Recent Clinical Trials:	See clinical trials for GENOTROPIN

See drug prices for GENOTROPIN

Recent Clinical Trials for GENOTROPIN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Foundation for Prader-Willi Research	Phase 3
Erasmus Medical Center	Phase 3
Prader-Willi Fonds	Phase 3

See all GENOTROPIN clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for GENOTROPIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for GENOTROPIN Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for GENOTROPIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280		2033-03-11	Patent claims search
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280		2034-11-02	Patent claims search
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280		2033-02-06	Patent claims search
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280		2030-12-23	Patent claims search
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280		2033-05-30	Patent claims search
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280		2034-09-04	Patent claims search

Market Dynamics and Financial Trajectory for the Biologic Drug: Genotropin

Introduction to Genotropin

Genotropin, a recombinant human growth hormone, is a pivotal biologic drug in the treatment of growth hormone deficiency and other related conditions. Manufactured by Pfizer, Genotropin has established itself as a significant player in the growth hormone deficiency market.

Market Size and Share

In 2023, Genotropin held the second-largest market share in the growth hormone deficiency market, generating revenues of USD 1.4 billion. This positioning is a testament to the drug's efficacy and the trust it has garnered among healthcare providers and patients[1][5].

Growth Projections

Genotropin is projected to continue its growth trajectory, with revenues expected to reach USD 2.1 billion by 2032. This growth is anticipated to be driven by several factors, including the increasing prevalence of growth hormone deficiency, improved diagnostic techniques, and enhanced patient access to treatment[1][5].

Competitive Landscape

Genotropin operates in a competitive market dominated by Norditropin, manufactured by Novo Nordisk. However, Genotropin's strong market presence is supported by its ability to support growth and immune function, although it may have limitations in specific patient populations. The competitive edge of Genotropin is further bolstered by Pfizer's extensive distribution network and strategic partnerships[1][5].

Financial Performance

The financial performance of Genotropin is closely tied to the overall financial health of its parent company, Pfizer, and its partner companies. For instance, OPKO Health, which receives gross profit share and royalty payments for Genotropin, reported an increase in these payments from $3.8 million in the second quarter of 2023 to $6.3 million in the second quarter of 2024. This increase reflects the growing demand and revenue generated by Genotropin[2].

Revenue Streams

The revenue streams for Genotropin are diverse and include sales through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. The expansion of online pharmacies and increased investments from global pharmaceutical companies have further enhanced the accessibility and sales of Genotropin[1][5].

Regional Analysis

Genotropin's market performance varies by region, with North America being a significant market due to the high prevalence of chronic diseases and favorable reimbursement policies. However, the Asia-Pacific region is forecasted to grow the fastest, driven by increasing healthcare infrastructure and growing awareness about biologic therapies[4][5].

Recent Developments and Innovations

Pfizer has been actively engaged in expanding the reach and improving the delivery of Genotropin. Recent developments include the expansion of Genotropin's global distribution network, focusing on emerging markets, and an R&D partnership with a biotech firm to develop a long-acting growth hormone therapy. These initiatives are expected to drive innovation and further solidify Genotropin's market position[5].

Market Drivers

Several factors drive the growth of the Genotropin market:

• Increasing Prevalence of Growth Hormone Deficiency: Early diagnosis and treatment needs are driving the demand for growth hormone therapies.
• Technological Advancements: Improvements in drug delivery systems, such as prefilled pen systems, enhance patient adherence and convenience.
• Strategic Partnerships: Collaborations with biotech firms and other pharmaceutical companies are leading to the development of new and innovative therapies.
• Expanding Distribution Channels: The growing presence of online pharmacies and enhanced global distribution networks are increasing access to Genotropin[1][5].

Challenges and Limitations

Despite its strong market position, Genotropin faces several challenges:

• Competition from Other Brands: Norditropin's dominance and other brands like Humatrope and Saizen pose significant competition.
• Limitations in Specific Patient Populations: Genotropin may not be as effective in certain patient groups, which can limit its market share.
• Regulatory and Reimbursement Challenges: Changes in regulatory environments and reimbursement policies can impact the drug's market performance[1][5].

Conclusion

Genotropin is a critical biologic drug in the treatment of growth hormone deficiency, with a strong market presence and promising growth projections. Its financial trajectory is influenced by its competitive positioning, regional market dynamics, and ongoing innovations in drug delivery and distribution.

Key Takeaways

• Market Share and Revenue: Genotropin held the second-largest market share in 2023 with revenues of USD 1.4 billion and is projected to reach USD 2.1 billion by 2032.
• Competitive Landscape: Genotropin competes with Norditropin and other brands, but its strong distribution network and strategic partnerships support its market position.
• Financial Performance: Increased royalty payments and expanding distribution channels contribute to Genotropin's financial growth.
• Regional Growth: North America is a significant market, but the Asia-Pacific region is expected to grow the fastest.
• Innovations and Developments: Recent expansions in distribution and R&D partnerships are driving innovation and market expansion.

FAQs

1. What is the current market share of Genotropin in the growth hormone deficiency market?

   • Genotropin holds the second-largest market share in the growth hormone deficiency market, generating revenues of USD 1.4 billion in 2023[1][5].

2. What are the projected revenues for Genotropin by 2032?

   • Genotropin is expected to reach revenues of USD 2.1 billion by 2032[1][5].

3. Who is the main competitor of Genotropin in the market?

   • The main competitor of Genotropin is Norditropin, manufactured by Novo Nordisk[1][5].

4. What are the key factors driving the growth of the Genotropin market?

   • Key factors include the increasing prevalence of growth hormone deficiency, technological advancements, strategic partnerships, and expanding distribution channels[1][5].

5. What recent developments have been made to enhance the delivery and accessibility of Genotropin?

   • Recent developments include the expansion of Genotropin's global distribution network and an R&D partnership to develop a long-acting growth hormone therapy[5].

Sources

1. SNS Insider: Growth Hormone Deficiency Market Size, Share & Analysis 2032
2. OPKO Health: OPKO Health Reports Second Quarter 2024 Business Highlights ...
3. BioSpace: Biologics Market Size to Reach USD 699.5 Billion by 2032, Impelled ...
4. BioSpace: Biologics Market Size to Hit Around USD 1.37 Trillion By 2033
5. GlobeNewswire: Growth Hormone Deficiency Market Size to Hit USD 8.5 Billion by 2032 - SNS Insider